Cannabis Law Report

OCTOBER 1, 2021

Virpax recently acquired global rights to VRP324, a product candidate for the intranasal delivery of a pharmaceutical-grade Schedule V cannabidiol (CBD) for the management of epilepsy in children, a rare pediatric disease. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the 16 years.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Data collection. Palliative care indications.

Research and Development 52

Research and Development Medicine Access Media 52

SMPL

MAY 26, 2020

And though a few outliers responded well to CBD alone, GW’s data showed that for relieving pain and inflammation, helping with sleep and alleviating seizures and spasms, most patients got the most benefit from an equal mix of CBD and THC — a drug the company called Sativex. The Stanleys told me their wait-list peaked at 15,000 names.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73